Global Alpha 1 Antitrypsin Deficiency Treatment Market Insights, Forecast to 2025

Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.
The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called "additional therapies"). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).
The global Alpha 1 Antitrypsin Deficiency Treatment market is valued at 1190 million US$ in 2018 and will reach 2560 million US$ by the end of 2025, growing at a CAGR of 10.1% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Alpha 1 Antitrypsin Deficiency Treatment market based on company, product type, end user and key regions.

This report studies the global market size of Alpha 1 Antitrypsin Deficiency Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Alpha 1 Antitrypsin Deficiency Treatment in these regions.
This research report categorizes the global Alpha 1 Antitrypsin Deficiency Treatment market by top players/brands, region, type and end user. This report also studies the global Alpha 1 Antitrypsin Deficiency Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
    Pfizer
    Baxter
    AstraZeneca
    Grifols
    Teva Pharmaceutical Industries
    Boehringer Ingelheim
    Kamada Ltd
    GlaxoSmithKline
    CSL Behring
    Shire
    LFB Biomedicaments
    Abeona Therapeutics
    Biogen
    Applied Genetic Technologies
    Baxalta
    Arrowhead Research Corporation
    ProBioGen
    Chiesi Pharmaceuticals
    Curaxys
    ProMetic Life Sciences

Market size by Product
    Augmentation Therapy
    Bronchodilators
    Corticosteroids
    Oxygen Therapy
Market size by End User
    Hospitals
    Specialty Clinics
    Pharmacies

Market size by Region
    North America
        United States
        Canada
        Mexico
    Asia-Pacific
        China
        India
        Japan
        South Korea
        Australia
        Indonesia
        Singapore
        Malaysia
        Philippines
        Thailand
        Vietnam
    Europe
        Germany
        France
        UK
        Italy
        Spain
        Russia
    Central & South America
        Brazil
        Rest of Central & South America
    Middle East & Africa
        GCC Countries
        Turkey
        Egypt
        South Africa

The study objectives of this report are:
    To study and analyze the global Alpha 1 Antitrypsin Deficiency Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
    To understand the structure of Alpha 1 Antitrypsin Deficiency Treatment market by identifying its various subsegments.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    Focuses on the key global Alpha 1 Antitrypsin Deficiency Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
    To project the value and sales volume of Alpha 1 Antitrypsin Deficiency Treatment submarkets, with respect to key regions.
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Alpha 1 Antitrypsin Deficiency Treatment are as follows:
    History Year: 2014-2018
    Base Year: 2018
    Estimated Year: 2019
    Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alpha 1 Antitrypsin Deficiency Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents

1 Study Coverage
    1.1  Alpha 1 Antitrypsin Deficiency Treatment Product
    1.2 Market Segments
    1.3 Key Manufacturers Covered
    1.4 Market by Type
        1.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Product
        1.4.2 Augmentation Therapy
        1.4.3 Bronchodilators
        1.4.4 Corticosteroids
        1.4.5 Oxygen Therapy
    1.5 Market by End User
        1.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End User
        1.5.2 Hospitals
        1.5.3 Specialty Clinics
        1.5.4 Pharmacies
    1.6 Study Objectives
    1.7 Years Considered

2 Executive Summary
    2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size
        2.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue 2014-2025
        2.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales 2014-2025
    2.2 Alpha 1 Antitrypsin Deficiency Treatment Growth Rate by Regions
        2.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales by Regions
        2.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Regions

3 Breakdown Data by Manufacturers
    3.1 Alpha 1 Antitrypsin Deficiency Treatment Sales by Manufacturers
        3.1.1 Alpha 1 Antitrypsin Deficiency Treatment Sales by Manufacturers
        3.1.2 Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Manufacturers
        3.1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
    3.2 Alpha 1 Antitrypsin Deficiency Treatment Revenue by Manufacturers
        3.2.1 Alpha 1 Antitrypsin Deficiency Treatment Revenue by Manufacturers (2014-2019)
        3.2.2 Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Manufacturers (2014-2019)
    3.3 Alpha 1 Antitrypsin Deficiency Treatment Price by Manufacturers
    3.4 Alpha 1 Antitrypsin Deficiency Treatment Manufacturing Base Distribution, Product Types
        3.4.1 Alpha 1 Antitrypsin Deficiency Treatment Manufacturers Manufacturing Base Distribution, Headquarters
        3.4.2 Manufacturers Alpha 1 Antitrypsin Deficiency Treatment Product Type
        3.4.3 Date of International Manufacturers Enter into Alpha 1 Antitrypsin Deficiency Treatment  Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
    4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales by Product
    4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Product
    4.3 Alpha 1 Antitrypsin Deficiency Treatment Price by Product

5 Breakdown Data by End User
    5.1 Overview
    5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End User

6 North America
    6.1 North America Alpha 1 Antitrypsin Deficiency Treatment by Countries
        6.1.1 North America Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries
        6.1.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries
        6.1.3 United States
        6.1.4 Canada
        6.1.5 Mexico
    6.2 North America Alpha 1 Antitrypsin Deficiency Treatment by Product
    6.3 North America Alpha 1 Antitrypsin Deficiency Treatment by End User

7 Europe
    7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment by Countries
        7.1.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries
        7.1.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries
        7.1.3 Germany
        7.1.4 France
        7.1.5 UK
        7.1.6 Italy
        7.1.7 Russia
    7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment by Product
    7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment by End User

8 Asia Pacific
    8.1 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment by Countries
        8.1.1 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries
        8.1.2 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries
        8.1.3 China
        8.1.4 Japan
        8.1.5 Korea
        8.1.6 India
        8.1.7 Australia
        8.1.8 Indonesia
        8.1.9 Malaysia
        8.1.10 Philippines
        8.1.11 Thailand
        8.1.12 Vietnam
        8.1.13 Singapore
    8.2 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment by Product
    8.3 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment by End User

9 Central & South America
    9.1 Central & South America Alpha 1 Antitrypsin Deficiency Treatment by Countries
        9.1.1 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries
        9.1.2 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries
        9.1.3 Brazil
    9.2 Central & South America Alpha 1 Antitrypsin Deficiency Treatment by Product
    9.3 Central & South America Alpha 1 Antitrypsin Deficiency Treatment by End User

10 Middle East and Africa
    10.1 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment by Countries
        10.1.1 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries
        10.1.2 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries
        10.1.3 GCC Countries
        10.1.4 Turkey
        10.1.5 Egypt
        10.1.6 South Africa
    10.2 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment by Product
    10.3 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment by End User

11 Company Profiles
    11.1 Pfizer
        11.1.1 Pfizer Company Details
        11.1.2 Company Business Overview
        11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.1.5 Pfizer Recent Development
    11.2 Baxter
        11.2.1 Baxter Company Details
        11.2.2 Company Business Overview
        11.2.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.2.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.2.5 Baxter Recent Development
    11.3 AstraZeneca
        11.3.1 AstraZeneca Company Details
        11.3.2 Company Business Overview
        11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.3.5 AstraZeneca Recent Development
    11.4 Grifols
        11.4.1 Grifols Company Details
        11.4.2 Company Business Overview
        11.4.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.4.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.4.5 Grifols Recent Development
    11.5 Teva Pharmaceutical Industries
        11.5.1 Teva Pharmaceutical Industries Company Details
        11.5.2 Company Business Overview
        11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.5.5 Teva Pharmaceutical Industries Recent Development
    11.6 Boehringer Ingelheim
        11.6.1 Boehringer Ingelheim Company Details
        11.6.2 Company Business Overview
        11.6.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.6.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.6.5 Boehringer Ingelheim Recent Development
    11.7 Kamada Ltd
        11.7.1 Kamada Ltd Company Details
        11.7.2 Company Business Overview
        11.7.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.7.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.7.5 Kamada Ltd Recent Development
    11.8 GlaxoSmithKline
        11.8.1 GlaxoSmithKline Company Details
        11.8.2 Company Business Overview
        11.8.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.8.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.8.5 GlaxoSmithKline Recent Development
    11.9 CSL Behring
        11.9.1 CSL Behring Company Details
        11.9.2 Company Business Overview
        11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.9.5 CSL Behring Recent Development
    11.10 Shire
        11.10.1 Shire Company Details
        11.10.2 Company Business Overview
        11.10.3 Shire Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.10.4 Shire Alpha 1 Antitrypsin Deficiency Treatment Products Offered
        11.10.5 Shire Recent Development
    11.11 LFB Biomedicaments
    11.12 Abeona Therapeutics
    11.13 Biogen
    11.14 Applied Genetic Technologies
    11.15 Baxalta
    11.16 Arrowhead Research Corporation
    11.17 ProBioGen
    11.18 Chiesi Pharmaceuticals
    11.19 Curaxys
    11.20 ProMetic Life Sciences

12 Future Forecast
    12.1 Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Regions
        12.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Forecast by Regions 2019-2025
        12.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Regions 2019-2025
    12.2 Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Product
        12.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Forecast by Product 2019-2025
        12.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Product 2019-2025
    12.3 Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by End User
    12.4 North America Alpha 1 Antitrypsin Deficiency Treatment Forecast
    12.5 Europe Alpha 1 Antitrypsin Deficiency Treatment Forecast
    12.6 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Forecast
    12.7 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Forecast
    12.8 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    13.1 Market Opportunities and Drivers
    13.2 Market Challenges
    13.3 Market Risks/Restraints
    13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
    14.1 Value Chain Analysis
    14.2 Alpha 1 Antitrypsin Deficiency Treatment Customers
    14.3 Sales Channels Analysis
        14.3.1 Sales Channels
        14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
    16.1 Research Methodology
        16.1.1 Methodology/Research Approach
        16.1.2 Data Source
    16.2 Author Details
    16.3 Disclaimer

List of Tables and Figures Figure Alpha 1 Antitrypsin Deficiency Treatment Product Picture Table Alpha 1 Antitrypsin Deficiency Treatment Market Segments Table Key Manufacturers Alpha 1 Antitrypsin Deficiency Treatment Covered Table Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Product 2019-2025 (K Units) & (Million US$) Figure Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Product 2014-2025 Figure Augmentation Therapy Product Picture Table Major Manufacturers of Augmentation Therapy Figure Bronchodilators Product Picture Table Major Manufacturers of Bronchodilators Figure Corticosteroids Product Picture Table Major Manufacturers of Corticosteroids Figure Oxygen Therapy Product Picture Table Major Manufacturers of Oxygen Therapy Table Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End User 2019-2025 (K Units) Figure Hospitals Figure Specialty Clinics Figure Pharmacies Figure Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market Size 2014-2025 (Million US$) Figure Global Alpha 1 Antitrypsin Deficiency Treatment Sales 2014-2025 (K Units) Table Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Regions 2014-2019 (K Units) & (Million US$) Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales by Regions 2014-2019 (K Units) Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Regions 2014-2019 Figure Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Regions 2014-2019 Figure 2018 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Regions Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Regions 2014-2019 (Million US$) Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Regions 2014-2019 Figure Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Regions 2014-2019 Figure 2018 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Regions Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales by Manufacturers (2014-2019) (K Units) Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Share by Manufacturers (2014-2019) Figure Global Alpha 1 Antitrypsin Deficiency Treatment Sales Share by Manufacturers in 2018 Table Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table Alpha 1 Antitrypsin Deficiency Treatment Revenue by Manufacturers (2014-2019) (Million USD) Table Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Manufacturers (2014-2019) Figure Alpha 1 Antitrypsin Deficiency Treatment Value Share by Manufacturers in 2018 Table Key Manufacturers Alpha 1 Antitrypsin Deficiency Treatment Price (2014-2019) (USD/Unit) Table Alpha 1 Antitrypsin Deficiency Treatment Manufacturers Manufacturing Base Distribution and Headquarters Table Manufacturers Alpha 1 Antitrypsin Deficiency Treatment Product Type Table Date of International Manufacturers Enter into Alpha 1 Antitrypsin Deficiency Treatment Market Table Manufacturers Mergers & Acquisitions, Expansion Plans Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales by Product (2014-2019) (K Units) Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Share by Product (2014-2019) Figure Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Product (2014-2019) Figure Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Product in 2018 Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Product (2014-2019) (Million US$) Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Product (2014-2019) Figure Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Product (2014-2019) Figure Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Product in 2018 Table Alpha 1 Antitrypsin Deficiency Treatment Price by Product 2014-2019 (USD/Unit) Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales by End User (2014-2019) (K Units) Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Share by End User (2014-2019) Figure Global Sales Alpha 1 Antitrypsin Deficiency Treatment Market Share by End User (2014-2019) Figure Global Sales Alpha 1 Antitrypsin Deficiency Treatment Market Share by End User in 2018 Figure North America Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate 2014-2019 (K Units) Figure North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate 2014-2019 (Million US$) Table North America Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries (2014-2019) (K Units) Table North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries (2014-2019) Figure 2018 North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries Table North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2014-2019) (Million US$) Table North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2014-2019) Figure 2018 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries Figure United States Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure United States Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (K Units) Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Table North America Alpha 1 Antitrypsin Deficiency Treatment Sales by Product (2014-2019) (K Units) Table North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Product (2014-2019) Figure 2018 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Product Table North America Alpha 1 Antitrypsin Deficiency Treatment Sales by End User (2014-2019) (K Units) Table North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End User (2014-2019) Figure 2018 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by End User Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate 2014-2019 (K Units) Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate 2014-2019 (Million US$) Table Europe Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries (2014-2019) (K Units) Table Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries (2014-2019) Figure 2018 Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries Table Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2014-2019) (Million US$) Table Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2014-2019) Figure 2018 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure France Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure France Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure UK Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure UK Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Table Europe Alpha 1 Antitrypsin Deficiency Treatment Sales by Product (2014-2019) (K Units) Table Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Product (2014-2019) Figure 2018 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Product Table Europe Alpha 1 Antitrypsin Deficiency Treatment Sales by End User (2014-2019) (K Units) Table Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End User (2014-2019) Figure 2018 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by End User Figure Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate 2014-2019 (K Units) Figure Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate 2014-2019 (Million US$) Table Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries (2014-2019) (K Units) Table Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries (2014-2019) Figure 2018 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries Table Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2014-2019) (Million US$) Table Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2014-2019) Figure 2018 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries Figure China Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure China Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure India Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure India Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Australia Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Australia Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Indonesia Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Indonesia Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Malaysia Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Malaysia Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Philippines Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Philippines Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Thailand Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Thailand Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Vietnam Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Vietnam Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Singapore Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Singapore Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Table Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales by Product (2014-2019) (K Units) Table Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Product (2014-2019) Figure 2018 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Product Table Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales by End User (2014-2019) (K Units) Table Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End User (2014-2019) Figure 2018 Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by End User Figure Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate 2014-2019 (K Units) Figure Central & South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate 2014-2019 (Million US$) Table Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries (2014-2019) (K Units) Table Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries (2014-2019) Figure 2018 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries Table Central & South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2014-2019) (Million US$) Table Central & South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2014-2019) Figure 2018 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries Figure Brazil Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Argentina Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Table Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales by Product (2014-2019) (K Units) Table Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Product (2014-2019) Figure 2018 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Product Table Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales by End User (2014-2019) (K Units) Table Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End User (2014-2019) Figure 2018 Central & South America Alpha 1 Antitrypsin Deficiency Treatment Market Share by End User Figure Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate 2014-2019 (K Units) Figure Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate 2014-2019 (Million US$) Table Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales by Countries (2014-2019) (K Units) Table Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries (2014-2019) Figure 2018 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Countries Table Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2014-2019) (Million US$) Table Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2014-2019) Figure 2018 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries Figure GCC Countries Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure GCC Countries Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate (2014-2019) (K Units) Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate (2014-2019) (Million US$) Table Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales by Product (2014-2019) (K Units) Table Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Product (2014-2019) Figure 2018 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Product Table Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales by End User (2014-2019) (K Units) Table Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End User (2014-2019) Figure 2018 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by End User Table Pfizer Company Details Table Pfizer Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table Pfizer Recent Development Table Baxter Company Details Table Baxter Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table Baxter Recent Development Table AstraZeneca Company Details Table AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table AstraZeneca Recent Development Table Grifols Company Details Table Grifols Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table Grifols Recent Development Table Teva Pharmaceutical Industries Company Details Table Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table Teva Pharmaceutical Industries Recent Development Table Boehringer Ingelheim Company Details Table Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table Boehringer Ingelheim Recent Development Table Kamada Ltd Company Details Table Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table Kamada Ltd Recent Development Table GlaxoSmithKline Company Details Table GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table GlaxoSmithKline Recent Development Table CSL Behring Company Details Table CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table CSL Behring Recent Development Table Shire Company Details Table Shire Alpha 1 Antitrypsin Deficiency Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019) Table Shire Recent Development Table LFB Biomedicaments Company Details Table Abeona Therapeutics Company Details Table Biogen Company Details Table Applied Genetic Technologies Company Details Table Baxalta Company Details Table Arrowhead Research Corporation Company Details Table ProBioGen Company Details Table Chiesi Pharmaceuticals Company Details Table Curaxys Company Details Table ProMetic Life Sciences Company Details Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Forecast by Regions 2019-2025 (K Units) Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share Forecast by Regions 2019-2025 Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Regions 2019-2025 (Million US$) Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share Forecast by Regions 2019-2025 Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Forecast by Product 2019-2025 (K Units) Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share Forecast by Product 2019-2025 Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Product 2019-2025 (Million US$) Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share Forecast by Product 2019-2025 Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Forecast by End User 2019-2025 (K Units) Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share Forecast by End User 2019-2025 Figure North America Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate Forecast (2019-2025) (K Units) Figure North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$) Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate Forecast (2019-2025) (K Units) Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$) Figure Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate Forecast (2019-2025) (K Units) Figure Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$) Figure Central & South America Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate Forecast (2019-2025) (K Units) Figure Central & South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$) Figure Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Growth Rate Forecast (2019-2025) (K Units) Figure Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$) Table Alpha 1 Antitrypsin Deficiency Treatment Value Chain Table Alpha 1 Antitrypsin Deficiency Treatment Customers List Table Alpha 1 Antitrypsin Deficiency Treatment Distributors List Table Research Programs/Design for This Report Figure Bottom-up and Top-down Approaches for This Report Figure Data Triangulation Table Key Data Information from Secondary Sources Table Key Data Information from Primary Sources

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Other Reports by QY Research

Global Long Walker Boot Market Professional Survey Report 2019

The global Long Walker Boot market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Long Walker Boot volume and value at global level, regional level an...

Global Undersea Cable Market Professional Survey Report 2019

The global Undersea Cable market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Undersea Cable volume and value at global level, regional level and co...

Global Syringes and Needles Market Professional Survey Report 2019

The global Syringes and Needles market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Syringes and Needles volume and value at global level, regional ...

Global Lip Glosses Market Professional Survey Report 2019

The global Lip Glosses market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Lip Glosses volume and value at global level, regional level and company ...

Global Rail Grease Market Professional Survey Report 2019

The global Rail Grease market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Rail Grease volume and value at global level, regional level and company ...

New Pharmaceuticals and Healthcare Reports

Publisher: QY Research 127 Pages   |  154 Tables